Stay updated on Tepotinib & Gefitinib in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Tepotinib & Gefitinib in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tepotinib & Gefitinib in NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page’s displayed site revision advances from v3.8.0 to v3.8.1.
    Difference
    0.0%
    Check dated 2026-11-18T03:11:19.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The clinical trial record for the Tep ಸೆotinib–gefitinib NSCLC study is available, including its completed status, eligibility criteria, treatment arms, outcomes, and study locations; it previously showed an access-denied error.
    Difference
    94%
    Check dated 2026-11-11T02:09:37.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page’s displayed site revision changed from v3.7.2 to v3.8.0. The study record itself still shows a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-04T00:41:23.000Z thumbnail image
  4. Check
    33 days ago
    Change Detected
    Summary
    An NIH-wide banner announces a transition from “Artificial Intelligence” to “Super Intelligence” terminology. The site revision label changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-21T00:43:52.000Z thumbnail image
  5. Check
    47 days ago
    Change Detected
    Summary
    The footer revision identifier was updated from v3.7.0 to v3.7.1 on the error page.
    Difference
    0.2%
    Check dated 2026-10-07T00:52:20.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, effectively blocking access to the study record. Most study-related navigation and document links appear to have been removed.
    Difference
    21%
    Check dated 2026-09-23T01:08:50.000Z thumbnail image

Stay in the know with updates to Tepotinib & Gefitinib in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tepotinib & Gefitinib in NSCLC Clinical Trial page.